| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c89ce4d9ac03f9acd8ddede1162f94d |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184 |
| filingDate |
2010-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ffb5d676e47dbef315fddbcfc747374
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2905e6da907a825fd3905df5178f3591
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e1a70fdbbf5d7caa2daf578ced0d75e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1687ba941ad6382b9fe0375f5699aa2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5453e0d05abbaa5243d858eeec43dea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78864585110a11dc808f79cd2b40753d |
| publicationDate |
2011-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2010253790-A1 |
| titleOfInvention |
Antiviral compounds composed of three aligned aryl moieties to treat diseases such as Hepatitis C |
| abstract |
The present invention relates to novel Tricyclic Compounds, compositions comprising at least one Tricyclic Compound, and methods of using Tricyclic Compounds for treating or preventing a viral infection or a virus-related disorder in a patient. The present invention provides Tricyclic Compounds of Formula (I): Non-limiting examples of the Compounds of Formula (I) include compound 44 The Compounds of Formula (II) can be useful for inhibiting HCV viral replication or replicon activity, and for treating or preventing HCV infection in a patient. |
| priorityDate |
2009-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |